The global digital breast tomosynthesis (DBT) equipment market is estimated to be valued at USD 3.26 billion in 2025 and is projected to reach USD 7.66 billion by 2035, registering a compound annual growth rate (CAGR) of 8.9% over the forecast period.
This growth is driven by the increasing prevalence of breast cancer, technological advancements in breast imaging, and rising awareness about the benefits of DBT over traditional mammography. DBT provides three-dimensional imaging, allowing for improved lesion detection and reduced false positives, which is particularly beneficial in dense breast tissues.
Key players such as Hologic, GE Healthcare, and Siemens Healthineers have reported in their annual presentations a significant uptick in DBT adoption across both developed and emerging markets, attributing this to enhanced diagnostic accuracy and patient outcomes.
Leading manufacturers are actively investing in product innovation and strategic collaborations to strengthen their market position. Key growth drivers include the rising incidence of breast cancer, increasing demand for early detection methods, and supportive government initiatives promoting breast cancer screening programs.
Additionally, technological advancements such as AI integration in DBT systems are enhancing image analysis, thereby improving diagnostic confidence among radiologists. This combination aims to address several unmet needs and challenges diagnostic imaging centres face towards effectively highlighting breast imaging abnormalities, which is especially beneficial in high-volume clinical settings.
-equipment-market.png "Digital Breast Tomosynthesis (DBT) Equipment Market")
Digital Breast Tomosynthesis (DBT) technology has many benefits which remain inefficient due to lack of specialized breast radiologists and streamlined workflows. In 2024, iCAD, Inc., a global leader in Ai-Powered Cancer Detection solution, has garnered FDA 510(k) clearance for their ProFound Detection Version 4.0, that offers advancement in Cancer detection with accuracy that improves precision and reduces false positive.
“With FDA clearance of ProFound Detection Version 4.0, iCAD continues to set new benchmarks in cancer detection, especially in the most challenging cases where accurate and early detection is critical,” said Dana Brown, President and CEO, iCAD. AI algorithms assist in identifying subtle lesions and reducing recall rates, thereby improving workflow efficiency. Furthermore, the development of synthetic 2D imaging from 3D DBT data has reduced radiation exposure, addressing safety concerns associated with repeated screenings.
North America remains the largest market for DBT equipment, holding a significant share due to advanced healthcare infrastructure, high awareness levels, and supportive reimbursement policies. The U.S., in particular, has witnessed increased adoption of DBT systems following recommendations from the FDA and the American College of Radiology endorsing DBT for breast cancer screening.
Additionally, continuous technological innovations by key players contributing to the market growth. Europe is experiencing substantial growth in the DBT equipment market, driven by rising breast cancer incidence and government-led screening programs.
All the Key countries have incorporated DBT into national screening guidelines, recognizing its superior diagnostic capabilities. Additionally, increasing investments in healthcare infrastructure and emphasis on early cancer detection are propelling market expansion in the region.
The 3D equipment segment dominates the market with a 64.9% revenue share in 2025. Its growth has been driven by its diagnostic superiority over conventional 2D mammography. In clinical settings, 3-D tomosynthesis has consistently demonstrated enhanced cancer detection rates and significantly reduced false positives, especially in women with dense breast tissue.
These advantages have led to strong physician preference and broadening institutional acceptance globally. In developed economies such as the USA, Germany, and the UK, adoption has been accelerated by favourable reimbursement frameworks and strong advocacy by clinical societies.
-equipment-market-by-product-type.png "Digital Breast Tomosynthesis (DBT) Equipment Market By Product Type")
Institutions in these countries have increasingly upgraded from analog and 2-D systems to 3-D-enabled platforms, as observed in procurement data from 2024 to 2025 published by health departments and radiology consortia. In developing economies, the uptake has been more gradual but promising. Government-led breast cancer screening initiatives in India, Brazil, and South Africa have begun to include 3-D DBT systems in public health tenders.
Cost barriers have been addressed through vendor financing models and donations via international health partnerships. As digital health infrastructure continues to improve, 3-D systems are expected to replace older 2-D systems, leading to broader diagnostic access and higher adoption across Tier II and Tier III cities in these region.
In 2025, the hospital segment is expected to dominate the Digital Breast Tomosynthesis (DBT) equipment market, holding over 66.9% of the total revenue share. This leadership position is attributed to expansive imaging infrastructure, greater capital availability and increasing integration of advanced breast cancer screening modalities into standard diagnostic workflows.
Hospitals have continued to invest heavily in upgrading their mammography suites with 3-D tomosynthesis equipment to comply with updated screening guidelines and enhance clinical accuracy. A surge in hospital-based breast cancer awareness programs and early detection initiatives-particularly in Europe and North America-has further driven equipment installations.
-equipment-market-analysis-by-end-user.png "Digital Breast Tomosynthesis (DBT) Equipment Market Analysis By End User")
Data from the European Society of Breast Imaging (EUSOBI) in 2024 highlighted that over 60% of hospital screening units across the EU had transitioned to tomosynthesis platforms. Additionally, multidisciplinary care models have gained prominence in tertiary care hospitals, where radiology, oncology, and surgery are integrated under one umbrella, necessitating high-end imaging modalities like DBT for coordinated decision-making.
The EUSOBI claimed that digital breast tomosynthesis (DBT) can be a viable alternative for increasing detection rates and decreasing recall rates in high volume centres. Recent developments in AI-augmented 3-D mammography systems have also been rapidly deployed in hospital settings.
Hospitals have been early adopters of such technologies due to their need for diagnostic precision and workflow efficiency. Consequently, hospital procurement has remained robust, positioning this segment as the primary revenue contributor in the global DBT equipment landscape.
North America is the dominant region in the DBT equipment market because of its strong healthcare infrastructure, high levels of breast cancer screening awareness, and presence of top imaging technology companies.
The USA, in particular, drives this expansion with favorable reimbursement policies, an AI-powered imaging solutions explosion, and increased funding for breast cancer research. The FDA's continued approval of cutting-edge DBT systems drives the market forward.
Nevertheless, the expense of DBT machinery and upkeep is still a challenge, particularly in rural regions where access to cutting-edge imaging continues to be an issue. The area is also experiencing a pick-up from increasing adoption of AI-based diagnostic software, the implementation of mobile screening vehicles, and government-supported breast cancer screening schemes.
In addition, partnerships between imaging firms and healthcare facilities are increasing, promoting innovation and enhancing diagnostic capacity, ultimately making breast cancer screening more available and precise.
Europe is the most significant region for the DBT equipment market due to high-level government initiatives towards early detection of breast cancer, increased application of AI-aided imaging, and innovations that enable reduced radiation doses. Germany, France, and the UK are the pioneers, aided by robust healthcare policies and considerable investment in digital health technologies.
However, tough EMA regulations and the cost-containment strategies of public healthcare systems do not make it easy for emerging DBT technologies to gain traction in the market. Nevertheless, there is much momentum.
Additional nations are attempting to add DBT to national breast cancer screening programs, and collaborations between medical imaging firms and research institutions are pushing innovation ahead.
The growth of teleradiology services also makes DBT technology more accessible to underserved regions, enhancing access to improved diagnostics devices. And the region's move toward value-based healthcare is driving more extensive adoption of DBT as part of integrated breast cancer care.
Asia-Pacific is rapidly advancing as an emerging market with tremendous growth potential for DBT equipment due to escalating breast cancer cases, a huge overhaul of healthcare infrastructure, and growing investment in cutting-edge medical imaging technology.
The key markets, namely China, Japan, and India, fueling growth are mainly supported by huge government efforts to expand breast cancer screening programs and enhance access to next-generation imaging solutions.
The market, however, also confronts other significant challenges. Substantial initial expenditures for DBT systems, insufficient numbers of trained radiologists, and varying levels of access to healthcare along urban-rural interfaces would ultimately restrain massive market penetration.
Nonetheless, increased implementation of artificial intelligence-based diagnostic solutions and widening private-owned healthcare sector systems are increasingly bridging the gap and ensuring market expansion.
Government and NGO-initiated breast cancer screening campaigns are playing an important role in boosting screening, while tactical partnerships between international imaging companies and regional healthcare systems are facilitating the installation of DBT systems in the region.
Furthermore, ramping up efforts to integrate DBT into national cancer screening programs will also continue to support market growth, thus positioning this segment as a pioneer in Asia-Pacific for DBT adoption.
Training Requirements and Workflow Challenges Restrain Market Growth
Implementation issues can be considered a restraining factor for the growth of the digital breast tomosynthesis (DBT) equipment market. Per the Mammography Quality Standards Act, the new modality training requirement for DBT includes 8 hours of training obtained on any DBT system or general DBT training.
It means that the dedicated professionals in the USA are required to complete eight hours of dedicated tomosynthesis training.
DBT image sets reading requires almost double the time required for interpretation of 2-D mammograms due to the bulk of images produced, that is, approx. 200 images compared to four for a 2-D view. Radiologists will need to learn to read master images.
Rising Adoption of 3-D Mammography Presents Growth Opportunities
The DBT imaging equipment market is poised for significant growth, courtesy of the increased uptake of 3-D mammography, which is superior to the old 2-D technology. In clinical trials after clinical trials, 3-D mammography has been shown to detect cancer more effectively, particularly invasive cancer, and thus, more healthcare practitioners are switching over.
This better precision ensures that fewer patients will have to take unnecessary biopsies, reducing expenses and rendering the whole process less traumatic for patients. These clear-cut advantages should increase demand for DBT machines, setting new possibilities for market expansion.
Advances in AI-Aided Imaging: AI-powered image analysis software is enhancing the accuracy of DBT scans, eliminating false positives, and aiding radiologists in early tumor detection, making the diagnosis more confident and efficient. AI-powered decision support tools are also being incorporated into DBT systems, enabling radiologists to prioritize high-risk cases more efficiently.
Regulatory and Policy Initiatives: Governments and health authorities are adopting policies to include DBT within national breast cancer screening programs through enhanced reimbursement coverage and standardized screening guidelines. Regulatory bodies are also pushing research on dose-optimized DBT solutions for weighing safety and efficacy.
Integration of AI-Powered Breast Imaging Solutions: AI application in DBT systems increases automation, maximizing image interpretation, and minimizing radiologist workload, resulting in quicker and more precise breast cancer diagnoses. AI-powered triage systems also optimize workflow efficiency by highlighting suspicious findings for radiologist evaluation.
Development of Ultra-Low-Dose and Portable DBT Systems: Continued research on minimizing radiation exposure with high image quality fuels the creation of safer DBT technologies to facilitate wider adoption in various healthcare environments. The development of small and mobile DBT units is also increasing access to breast imaging in outpatient clinics and community health centers.
The market for Digital Breast Tomosynthesis (DBT) machines has grown consistently with the improvement in imaging technologies, rising awareness about early detection of breast cancer, and the growing rate of breast cancer globally. Increasing attention toward individualized treatment and premature screening for cancer continued to push DBT for general adoption by standard mammography practices.
While the medical fraternity has rapidly experienced technology improvements, combining machine learning with AI for implementing them in DBT platforms intensified at this juncture as image analysis benefited from such incorporations, boosting diagnosis accuracy and decreasing reader time for radiologists.
Medical imaging facilities embraced cutting-edge DBT systems with automated workflows, reduced radiation doses, and improved imaging software to address the growing need for high-throughput and efficient screening.
Government campaigns for raising awareness about breast cancer and breast cancer screening programs in developed and emerging economies also accelerated the growth of the DBT market, creating new avenues for equipment suppliers and service providers.
Sustainability and patient safety became focal points, motivating the creation of energy-efficient technologies, eco-friendly components, and innovative shielding techniques to reduce radiation exposure.
To remain competitive and meet changing market demands, companies spent substantial research and development, traversed challenging regulatory processes, and established strategic alliances to strengthen their global positions and products, ultimately facilitating the expanding demand for quality DBT systems in breast cancer screening tests and diagnostics.
| Category | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Focus on the safety and effectiveness of DBT devices, with regulatory authorities allowing approvals of high-end imaging machines. |
| Technological Advancements | The usage of 2D/3D combination technology increases diagnostic sensitivity and workflow for the detection of breast cancer. |
| Consumer Demand | Greater awareness for more demand of early and accurate detection of breast cancer, using non-invasive and effective diagnosis equipment. |
| Market Growth Drivers | Increasing prevalence of breast cancer, technological advancements in imaging, and expansion in the healthcare sector of developed economies. |
| Sustainability | Leading endeavors in green manufacturing and reducing the carbon footprint of medical devices. |
| Supply Chain Dynamics | Relyence on tested-trusted distribution networks, with product availability in hospital and diagnostics channels being a principal concern. |
| Category | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Deployment of extensive guidelines for AI-aided DBT systems to guarantee uniform protocols and data security features. |
| Technological Advancements | Adoption of machine learning and AI algorithms to enhance image interpretation, create transportable DBT devices, and evolve 3D imaging technologies. |
| Consumer Demand | Increased desire for customized and accurate diagnostic products, with patients looking for state-of-the-art imaging technology that provides clear information about breast health and enables individualized treatment programs. |
| Market Growth Drivers | Penetration in emerging economies with enhanced healthcare infrastructure, rising investments in research and development of advanced imaging technologies, and strategic partnerships among medical device companies and healthcare providers. |
| Sustainability | Total embracing of sustainable processes such as deploying recyclable materials, environmentally friendly manufacturing operations, and electronic waste reduction practices linked to medical devices. |
| Supply Chain Dynamics | Optimization of supply chains using digital technology, increasing transparency and efficiency, and timely delivery of devices into varied healthcare facilities, including far-flung and underserved areas. |
Market Outlook
Rising chronic diseases such as breast cancer, the leading cancer in women in the United States, have created a greater demand for sophisticated diagnostic systems DBT. Other advanced imaging technologies have been embraced by healthcare professionals throughout the USA, as they also enable imaging of higher quality than traditional 2-D mammography but are primarily aimed at early detection and precise diagnosis.
The American medical device industry is competitive and has several manufacturers and suppliers specializing in DBT equipment, software, and accessories. Awareness creation campaigns, government screening programs, and increased healthcare spending have consistently propelled the demand for the incorporation of credible, non-invasive imaging methods in the detection of improved breast cancer cases, thereby enhancing better patient outcomes.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 7.5% |
Market Outlook
Germany's advanced healthcare system, combined with its high priority on preventive care and awareness of breast cancer screening, strongly drives the DBT market in Germany. Furthermore, the country has introduced DBT technology into established breast cancer screening programs based on increased accuracy and reduced false positive results over present mammography.
German healthcare providers prefer high accuracy and precision, driving the demand for cutting-edge DBT systems with AI integration to fine-tune the diagnostic workflow. The stringent regulation on standards and advantageous reimbursement policies further encourage hospitals and diagnostic centers to invest in DBT machines, positioning Germany as an unrivaled leader in medical imaging across Europe.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 6.0% |
Market Outlook
The growing Chinese DBT market is driven by the country's strengthening health infrastructure and rising government contributions to advanced medical technologies. In conjunction with increasing public awareness for early detection, these factors are majorly boosting DBT system demand in China owing to rising incidences of breast cancer.
The Chinese elderly population further adds to the burden of diagnosis, necessitating accurate and effective screening methods. Manufacturers in this country are growing proactive in the market by providing low-cost DBT solutions, particularly required by urban and rural facilities. It is mainstream government endeavours such as breast cancer screening programs and health reforms that endorse the introduction of DBT technology across the country.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| China | 9.2% |
Market Outlook
The Indian Digital Breast Tomosynthesis market has been envisioned to grow owing to the high incidence of breast cancer and rising awareness on the urgent need for early diagnosis. However, high-tech healthcare access is a major challenge in the rural regions of India.
The private sector is booming, while there are several steps taken towards the betterment of healthcare access through government-led health initiatives, such as Ayushman Bharat. In the process, more women in urban and semi-urban regions have better access to breast cancer screening, thus propelling DBT adoption.
Nevertheless, cost remains a key driver for India; there is a high demand for reasonably priced and portable DBT systems. The private diagnostic centers, in collaboration with government health programs, are set to widen the reach of DBT technology to a larger segment of the population.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 8.6% |
Market Outlook
The Brazilian market for DBT is being driven by increasing promotional efforts for screening programs related to breast cancer by various public health programs. The government of Brazil is contributing its share to make the initiation of this venture by becoming more and more proactive in generating awareness through nationwide campaigns for early detection, like "Outubro Rosa" or "Pink October," which in turn has increased awareness and fueled demand for cutting-edge mammography solutions like DBT.
Private health is involved in such evolution, with large-level urban locations demanding this new technology and driving it through an increasing tide of specialist diagnostic centers for quick implementation in the wake of anticipated economic downturns.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Brazil | 4.6% |
To strengthen their presence around the globe and improve their business strategies, the key players are involved in various expansions, collaborations, and mergers and acquisitions. These are the top three key promotional strategies adopted by the key players in the digital breast tomosynthesis (DBT) equipment market.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Hologic, Inc. | 23.5% |
| GE Healthcare | 19.1% |
| Siemens Healthineers | 13.4% |
| Fujifilm Holdings Corp. | 9.2% |
| Canon Medical Systems | 4.5% |
| Other Companies (combined) | 30.1% |
| Company Name | Key Offerings/Activities |
|---|---|
| Hologic, Inc. | Market leader offering Selenia Dimensions and 3D Mammography solutions with AI-enhanced imaging. |
| GE Healthcare | Develop advanced DBT systems, including Senographe Pristina, focusing on patient comfort and high image clarity. |
| Siemens Healthineers | Specializes in 3D breast imaging solutions, including Mammomat Inspiration with automated workflow integration. |
| Fujifilm Holdings Corp. | Provides Aspire Cristalle, an innovative DBT system featuring advanced detector technology for high-resolution imaging. |
| Canon Medical Systems | Offers cutting-edge digital mammography and DBT systems with integrated artificial intelligence. |
Key Company Insights
Hologic, Inc. (23.5%)
A dominant player in the DBT market, Hologic leads with AI-powered 3D mammography and a strong focus on early breast cancer detection.
GE Healthcare (19.1%)
A leader in diagnostic imaging, GE Healthcare’s Senographe Pristina system emphasizes patient-centered design and high-resolution imaging.
Siemens Healthineers (13.4%)
A key innovator in breast imaging, Siemens integrates automated workflow and AI-driven enhancements in its DBT systems.
Fujifilm Holdings Corp. (9.2%)
Known for its high-performance imaging detectors, Fujifilm’s Aspire Cristalle DBT system enhances image quality while reducing radiation exposure.
Canon Medical Systems (4.5%)
A growing competitor in medical imaging, Canon focuses on AI-driven diagnostic solutions for breast cancer detection.
Beyond the leading companies, several other manufacturers contribute significantly to the market, enhancing product diversity and technological advancements. These include
The overall market size for digital breast tomosynthesis (DBT) equipment market was USD 3.26 billion in 2025.
The digital breast tomosynthesis (DBT) equipment Market is expected to reach USD 7.66 billion in 2035.
The increasing global prevalence of breast cancer is driving demand for advanced diagnostic tools like DBT to enable early and accurate detection.
The top key players that drives the development of digital breast tomosynthesis (DBT) equipment market are Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corp. and Canon Medical Systems
3-D equipment in product type of digital breast tomosynthesis (DBT) equipment market is expected to command significant share over the assessment period.
Explore Diagnostic Devices Insights
Digital Breast Tomosynthesis (DBT) Equipment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
